Bonjour and welcome to the 40th meeting of the Standing Committee on Industry, Science and Technology.
We have before us a number of witnesses, as well as witnesses by teleconference. I'll introduce them.
From the Canadian Generic Pharmaceutical Association, we have Jim Keon, the president, and Benjamin Gray, vice-president, and legal and general counsel of Mylan Pharmaceuticals ULC.
From the Ontario Bioscience Innovation Organization, we have Gail Garland, who is the president and chief executive officer.
We also have with us George Dixon, the vice-president of research at the University of Waterloo, who is appearing as an individual.
By video conference, we have Norman Siebrasse, who is appearing as an individual. He is a professor in thefaculty of law at the University of New Brunswick.
We will begin with Jim Keon.
Please contain your opening remarks to six minutes as we have five witnesses.
I would also ask members to remember, once we get into the questioning, that we do have somebody by video conference. I know it's easy to focus on the witnesses at the end of the table and leave out the person who is joining us by video conference. I'm certain that Mr. Siebrasse would not enjoy that.
Mr. Keon, please give us your opening remarks.